Frontiers in Pharmacology (Sep 2018)
Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis
- Clement C. Zai,
- Clement C. Zai,
- Clement C. Zai,
- Clement C. Zai,
- Frankie H. Lee,
- Arun K. Tiwari,
- Arun K. Tiwari,
- Justin Y. Lu,
- Vincenzo de Luca,
- Vincenzo de Luca,
- Vincenzo de Luca,
- Miriam S. Maes,
- Miriam S. Maes,
- Deanna Herbert,
- Anashe Shahmirian,
- Sheraz Y. Cheema,
- Gwyneth C. Zai,
- Gwyneth C. Zai,
- Anupama Atukuri,
- Michael Sherman,
- Sajid A. Shaikh,
- Maria Tampakeras,
- Natalie Freeman,
- Nicole King,
- Daniel J. Müller,
- Daniel J. Müller,
- Daniel J. Müller,
- Lior Greenbaum,
- Lior Greenbaum,
- Lior Greenbaum,
- Bernard Lerer,
- Aristotle N. Voineskos,
- Aristotle N. Voineskos,
- Aristotle N. Voineskos,
- Steven G. Potkin,
- Jeffrey A. Lieberman,
- Herbert Y. Meltzer,
- Gary Remington,
- Gary Remington,
- Gary Remington,
- James L. Kennedy,
- James L. Kennedy,
- James L. Kennedy
Affiliations
- Clement C. Zai
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Clement C. Zai
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Clement C. Zai
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Clement C. Zai
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
- Frankie H. Lee
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Arun K. Tiwari
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Arun K. Tiwari
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Justin Y. Lu
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Vincenzo de Luca
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Vincenzo de Luca
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Vincenzo de Luca
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Miriam S. Maes
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Miriam S. Maes
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Deanna Herbert
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Anashe Shahmirian
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Sheraz Y. Cheema
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Gwyneth C. Zai
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Gwyneth C. Zai
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Anupama Atukuri
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Michael Sherman
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Sajid A. Shaikh
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Maria Tampakeras
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Natalie Freeman
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Nicole King
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Daniel J. Müller
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Daniel J. Müller
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Daniel J. Müller
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Lior Greenbaum
- The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel
- Lior Greenbaum
- The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel
- Lior Greenbaum
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Bernard Lerer
- Biological Psychiatry Laboratory and Hadassah BrainLabs, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- Aristotle N. Voineskos
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Aristotle N. Voineskos
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Aristotle N. Voineskos
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Steven G. Potkin
- Department of Psychiatry and Human Behavior, Long Beach Veterans Administration Health Care System, University of California, Irvine, Irvine, CA, United States
- Jeffrey A. Lieberman
- 0Columbia University, New York State Psychiatric Institute, New York City, NY, United States
- Herbert Y. Meltzer
- 1Psychiatry and Behavioral Sciences, Pharmacology and Physiology, Chemistry of Life Processes Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
- Gary Remington
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Gary Remington
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Gary Remington
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- James L. Kennedy
- Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- James L. Kennedy
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- James L. Kennedy
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- DOI
- https://doi.org/10.3389/fphar.2018.00974
- Journal volume & issue
-
Vol. 9
Abstract
Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however, genetic factors play an important role. The Perlecan (HSPG2) gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. To add to the evidence for this gene in TD, we conducted a meta-analysis specific to the relationship of HSPG2 rs2445142 with TD occurrence, while also adding our unpublished genotype data. Overall, we found a significant association of the G allele with TD occurrence (p = 0.0001); however, much of the effect appeared to originate from the discovery dataset. Nonetheless, most study samples exhibit the same trend of association with TD for the G allele. Our findings encourage further genetic and molecular studies of HSPG2 in TD.
Keywords
- pharmacogenetics
- tardive dyskinesia
- schizophrenia
- perlecan/heparan sulfate proteoglycan 2 (HSPG2)
- meta-analysis
